+ 12,3 % bei Geron (902213) Was ist los? o. T.

150 Mio. $ Offering

Was für eine Verwässerung!

https://ir.geron.com/investors/press-releases/...arrants/default.aspx

https://seekingalpha.com/news/...essure-after-pricing-equity-offering

Zahlen für Q2/20

• keine Umsätze
  
• Verlust 16 Mio. $
  
• Cash 265 Mio. $
  
• MK 546 Mio. $
  

"Based on current planning assumptions, the Company expects such funds to be sufficient for its operations into the second half of 2022 when top-line results for the IMerge Phase 3 clinical trial in lower risk MDS and completion of patient enrollment for the planned Phase 3 clinical trial in refractory MF are expected."

https://ir.geron.com/investors/press-releases/...-Events/default.aspx

Zahlen für Q2/21

• keine Umsätze
  
• Verlust 30 Mio. $
  
• Cash 239 Mio. $
  
• MK 405 Mio. $
  

These financial resources, combined with expected future non-dilutive funding under the current debt facility, are now expected to fund operations through the end of the first quarter of 2023.

?We are pleased with the achievement of 91% of the planned enrollment in IMerge Phase 3 and expect the trial to be fully enrolled in the fourth quarter of 2021. In addition, the expected timing for top-line results in IMerge Phase 3 has been accelerated by three months to the first quarter of 2023,?

https://ir.geron.com/investors/press-releases/...of-2023/default.aspx